Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An instance of ovarian cancer that is caused by an inherited modification of the individual's genome.
Biomarker and diagnostic research for familial ovarian cancer has been reported in the published literature.
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
123 publications have been identified in PubMed for familial ovarian cancer. Kisho has analyzed 43 by research type. Research spans Review / Meta-Analysis (42%), Basic Science / Preclinical (33%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 18 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 12:34 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research | 14 | 33% |
Disease patterns and progression | 5 | 12% |
Testing and diagnosis research | 3 | 7% |
New treatment approaches | 2 | 5% |
Clinical study results | 1 | 2% |
Krishna BM (2026). [PMID: 41643795](https://pubmed.ncbi.nlm.nih.gov/41643795/). *Crit Rev Oncol Hematol*. [Review / Meta-Analysis]
Boyraz B (2026). [PMID: 41036825](https://pubmed.ncbi.nlm.nih.gov/41036825/). *Am J Surg Pathol*. [Diagnostic / Biomarker]
Scott CL (2026). [PMID: 41786760](https://pubmed.ncbi.nlm.nih.gov/41786760/). *Nat Rev Dis Primers*. [Review / Meta-Analysis]
Cheng HH (2026). [PMID: 41671423](https://pubmed.ncbi.nlm.nih.gov/41671423/). *J Natl Compr Canc Netw*. [Review / Meta-Analysis]
Chui MH (2025). [PMID: 40327333](https://pubmed.ncbi.nlm.nih.gov/40327333/). *Clin Cancer Res*. [Basic Science / Preclinical]
Ju S (2025). [PMID: 40399985](https://pubmed.ncbi.nlm.nih.gov/40399985/). *J Ovarian Res*. [Review / Meta-Analysis]
Ren F (2025). [PMID: 40093000](https://pubmed.ncbi.nlm.nih.gov/40093000/). *Front Immunol*. [Basic Science / Preclinical]
Talbot L (2025). [PMID: 39138622](https://pubmed.ncbi.nlm.nih.gov/39138622/). *Pediatr Blood Cancer*. [Review / Meta-Analysis]
Wang L (2025). [PMID: 40706920](https://pubmed.ncbi.nlm.nih.gov/40706920/). *Int J Biol Macromol*. [Basic Science / Preclinical]
Titcomb CP (2025). [PMID: 40983328](https://pubmed.ncbi.nlm.nih.gov/40983328/). *J Insur Med*. [Review / Meta-Analysis]